Alpha Cognition Inc
ACOG
Rang in Aktien
#20051
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aktienkurs
$8.63
Marktkapitalisierung
$134.04M
Veränderung (1 Tag)
0.23%
Veränderung (1 Jahr)
71.57%
Land
US
Handel Alpha Cognition Inc (ACOG)
Kategorie
Healthcare
Kursverlauf für Alpha Cognition Inc (ACOG)
Höchster Schlusskurs: $5.46 am 2024-12-01
Niedrigster Schlusskurs: $18.75 am 2021-06-01
Niedrigster Schlusskurs: $18.75 am 2021-06-01
Kursverlauf der Aktie von Alpha Cognition Inc von 2021 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2024 | -51.49% |
| 2023 | 87.35% |
| 2022 | -73.46% |
| 2021 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $136.67 | -4.47% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
